

Bimmer E Claessen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3211157/publications.pdf>

Version: 2024-02-01

209
papers

6,971
citations

66343

42
h-index

69250

77
g-index

260
all docs

260
docs citations

260
times ranked

6606
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2022, 43, e17-e25.	2.2	92
2	DEtection of Proximal Coronary stenosis in the work-up for Transcatheter aortic valve implantation using CTA (from the DEPICT CTA collaboration). <i>European Radiology</i> , 2022, 32, 143-151.	4.5	10
3	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 380-389.	2.1	4
4	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 20-29.	2.1	8
5	Recovery of right ventricular function and strain in patients with ST-segment elevation myocardial infarction and concurrent chronic total occlusion. <i>International Journal of Cardiovascular Imaging</i> , 2022, 38, 631-641.	1.5	1
6	Contemporary coronary artery bypass graft surgery and subsequent percutaneous revascularization. <i>Nature Reviews Cardiology</i> , 2022, 19, 195-208.	13.7	34
7	Impact of Race/Ethnicity on Long Term Outcomes After Percutaneous Coronary Intervention with Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2022, , .	1.6	0
8	Identification and treatment of the vulnerable coronary plaque. <i>Reviews in Cardiovascular Medicine</i> , 2022, 23, 1.	1.4	10
9	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris. <i>American Journal of Cardiology</i> , 2022, 168, 47-54.	1.6	4
10	Detection of Vulnerable Coronary Plaques Using Invasive and Non-Invasive Imaging Modalities. <i>Journal of Clinical Medicine</i> , 2022, 11, 1361.	2.4	14
11	Current State and Future Perspectives of Artificial Intelligence for Automated Coronary Angiography Imaging Analysis in Patients with Ischemic Heart Disease. <i>Current Cardiology Reports</i> , 2022, 24, 365-376.	2.9	6
12	Residual Inflammatory Risk After Percutaneous Coronary Intervention. <i>JACC Asia</i> , 2022, , .	1.5	0
13	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, CIRCINTERVENTIONS120009495.	3.9	4
14	Considerations for Optimal Device Selection in Transcatheter Aortic Valve Replacement. <i>JAMA Cardiology</i> , 2021, 6, 102-112.	6.1	19
15	Predictors and outcomes of procedural failure of percutaneous coronary intervention of a chronic total occlusionâ€”A subanalysis of the EXPLORE trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1176-1183.	1.7	2
16	Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 225-235.	3.0	40
17	Safety and efficacy of the bioabsorbable polymer everolimusâ€”eluting stent versus durable polymer drugâ€”eluting stents in highâ€”risk patients undergoing PCI : TWILIGHTâ€”SYNERGY. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 63-71.	1.7	6
18	Impact of diabetes mellitus on female subjects undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI international registry. <i>International Journal of Cardiology</i> , 2021, 322, 65-69.	1.7	3

#	ARTICLE	IF	CITATIONS
19	Preprocedural anemia in females undergoing transcatheter aortic valve implantation: Insights from the WIN-TAVI registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E704-E715.	1.7	8
20	A sex paradox in clinical outcomes following complex percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2021, 329, 67-73.	1.7	11
21	Radial versus femoral access for coronary interventions: An updated systematic review and meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 1387-1396.	1.7	42
22	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 419-428.	2.1	2
23	Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 649-657.	3.3	7
24	White blood cell count and clinical outcomes after left main coronary artery revascularization. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, 45-51.	0.7	0
25	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2432-2447.	2.8	17
26	Impact of sex on long-term cardiovascular outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E494-E500.	1.7	2
27	Incidence, predictors and clinical impact of permanent pacemaker insertion in women following transcatheter aortic valve implantation: Insights from a prospective multinational registry. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E908-E917.	1.7	7
28	Cangrelor Use in Routine Practice: A Two-Center Experience. <i>Journal of Clinical Medicine</i> , 2021, 10, 2829.	2.4	1
29	Long-term 5-year outcome of the randomized IMPRESS in severe shock trial: percutaneous mechanical circulatory support vs. intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1009-1015.	1.0	30
30	Impact of target vessel choice on outcomes following percutaneous coronary intervention in patients with a prior coronary artery bypass graft. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E785-E795.	1.7	2
31	Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey. <i>European Heart Journal</i> , 2021, 42, 339-351.	2.2	57
32	The Impact of Percutaneous Coronary Intervention on Mortality in Patients With Coronary Lesions Who Underwent Transcatheter Aortic Valve Replacement. <i>Journal of Invasive Cardiology</i> , 2021, 33, E823-E832.	0.4	0
33	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention—Results from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 885-892.	1.7	5
34	Paclitaxel-coated balloon angioplasty vs. drug-eluting stenting for the treatment of coronary in-stent restenosis: a comprehensive, collaborative, individual patient data meta-analysis of 10 randomized clinical trials (DAEDALUS study). <i>European Heart Journal</i> , 2020, 41, 3715-3728.	2.2	121
35	Recovery and prognostic value of myocardial strain in ST-segment elevation myocardial infarction patients with a concurrent chronic total occlusion. <i>European Radiology</i> , 2020, 30, 600-608.	4.5	13
36	Impact of stent diameter on outcomes following percutaneous coronary intervention with second-generation drug-eluting stents: Results from a large single-center registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 558-564.	1.7	6

#	ARTICLE	IF	CITATIONS
37	Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study). American Journal of Cardiology, 2020, 125, 685-693.	1.6	1
38	TCT CONNECT-162 Predictors of Adverse Events in Patients Undergoing Cardiac Surgery Within 1 Year of PCI. Journal of the American College of Cardiology, 2020, 76, B69-B70.	2.8	0
39	TCT CONNECT-305 Impact of Lesion Location on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents for Unprotected Left Main Coronary Artery Stenosis. Journal of the American College of Cardiology, 2020, 76, B131-B132.	2.8	0
40	TCT CONNECT-307 Long-Term Outcomes After Coronary Intervention With Drug Eluting Stents for Unprotected Left Main Coronary Artery Stenosis According to Diabetes Mellitus Status. Journal of the American College of Cardiology, 2020, 76, B132-B133.	2.8	1
41	Impact of High-Density Lipoprotein Levels on Cardiovascular Outcomes of Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. American Journal of Cardiology, 2020, 137, 1-6.	1.6	0
42	Improving the Design of Future PCI Trials for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 76, 435-450.	2.8	7
43	IMPACT OF INCOMPLETE REVASCULARIZATION OF THE LEFT ANTERIOR DESCENDING ARTERY VERSUS OTHER CORONARY ARTERIES AFTER PCI: INSIGHTS FROM THE RIVER-PCI TRIAL. Journal of the American College of Cardiology, 2020, 75, 192.	2.8	0
44	FFR in the Setting of ACS. JACC: Cardiovascular Interventions, 2020, 13, 1904-1906.	2.9	2
45	TCT CONNECT-379 Adverse Outcomes in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 76, B163.	2.8	0
46	Stent Technology Reaches Maturity?. JACC: Cardiovascular Interventions, 2020, 13, 2879-2881.	2.9	1
47	Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review. Journal of the American Heart Association, 2020, 9, e018897.	3.7	23
48	Implications of Kidney Disease in the Cardiac Patient. Interventional Cardiology Clinics, 2020, 9, 265-278.	0.4	2
49	Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation. JACC: Cardiovascular Interventions, 2020, 13, 1417-1428.	2.9	77
50	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008226.	3.9	21
51	Impact of insulin treated and non-insulin-treated diabetes compared to patients without diabetes on 1-year outcomes following contemporary PCI. Catheterization and Cardiovascular Interventions, 2020, 96, 298-308.	1.7	11
52	The impact of chronic kidney disease in women undergoing transcatheter aortic valve replacement: Analysis from the Women's International Transcatheter Aortic Valve Implantation (WITAVI) registry. Catheterization and Cardiovascular Interventions, 2020, 96, 198-207.	1.7	13
53	The importance of the Heart Team evaluation before transcatheter aortic valve replacement: Results from the BRAVO trial. Catheterization and Cardiovascular Interventions, 2020, 96, E688-E694.	1.7	1
54	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. Circulation, 2020, 141, 891-901.	1.6	28

#	ARTICLE	IF	CITATIONS
55	Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. <i>Clinical Research in Cardiology</i> , 2020, 109, 725-734.	3.3	5
56	Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. <i>Journal of the American Heart Association</i> , 2020, 9, e014611.	3.7	12
57	Drug-Coated Balloon Angioplasty Versus Drug-Eluting Stent Implantation in Patients With Coronary Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2664-2678.	2.8	93
58	RESIDUAL INFLAMMATORY RISK IN PATIENTS WITH CHRONIC KIDNEY DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1357.	2.8	0
59	IMPACT OF GENDER AND RACE ON OUTCOMES AFTER COMPLEX PERCUTANEOUS CORONARY INTERVENTION WITH THE PLATINUM-CHROMIUM EVEROLIMUS-ELUTING STENT: A POOLED ANALYSIS OF THE PLATINUM DIVERSITY AND PROMUS ELEMENT PLUS POST-APPROVAL STUDIES. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1358.	2.8	0
60	TCT-307 Vascular Closure Device Use After PCI for Left Main Disease: Analysis From the EXCEL Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B305.	2.8	0
61	TCT-315 White Blood Cell Count and 4-Year Clinical Outcomes After Left Main Coronary Artery Revascularization: Insights From the EXCEL Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B313.	2.8	0
62	TCT-662 Patients Who Do Not Receive Drug-Eluting Stent for In-Stent Restenosis: Characteristics and Outcomes. <i>Journal of the American College of Cardiology</i> , 2019, 74, B650.	2.8	0
63	TCT-686 The Impact of Coronary Artery Disease and Pre-Procedural PCI on the Short- and Long-Term Mortality After TAVR. <i>Journal of the American College of Cardiology</i> , 2019, 74, B673.	2.8	0
64	TCT-214 Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Chronic Total Coronary Occlusions: A Systematic Review and Meta-Analysis of Randomized Trials. <i>Journal of the American College of Cardiology</i> , 2019, 74, B213.	2.8	0
65	Impact of diabetes mellitus on short term vascular complications after TAVR: Results from the BRAVO-3 randomized trial. <i>International Journal of Cardiology</i> , 2019, 297, 22-29.	1.7	10
66	Minding the Microcirculation. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008312.	3.9	0
67	Complementary role of cardiac computed tomography angiography in the diagnosis of prosthetic aortic valve endocarditis and septic coronary embolism - a case report. <i>Journal of Radiology Case Reports</i> , 2019, 13, 9-14.	0.4	0
68	Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 82-90.	1.7	10
69	ST-segment elevation myocardial infarction. <i>Nature Reviews Disease Primers</i> , 2019, 5, 39.	30.5	179
70	Outcomes by Gender and Ethnicity After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2019, 123, 1941-1948.	1.6	9
71	Impact of percutaneous closure device type on vascular and bleeding complications after TAVR: A post hoc analysis from the BRAVO-3 randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1374-1381.	1.7	35
72	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 983-992.	2.9	12

#	ARTICLE	IF	CITATIONS
73	Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2019, 73, 2401-2409.	2.8	69
74	600.09 In-Hospital Outcomes of Patients with Bicuspid Aortic Valve Undergoing Transcatheter Aortic Valve Replacement: A Nationwide Analysis. JACC: Cardiovascular Interventions, 2019, 12, S45.	2.9	1
75	Exercise testing after chronic total coronary occlusion revascularization in patients with STEMI and a concurrent CTO: A subanalysis of the EXPLORE trial. Catheterization and Cardiovascular Interventions, 2019, 94, 536-545.	1.7	3
76	Effect of stent diameter in women undergoing percutaneous coronary intervention with early- and new-generation drug-eluting stents: From the WIN-DES collaboration. International Journal of Cardiology, 2019, 287, 59-61.	1.7	8
77	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2019, 12, e007133.	3.9	17
78	Hope for the best, prepare for the worst: How to manage coronary perforations. Catheterization and Cardiovascular Interventions, 2019, 93, E255-E256.	1.7	2
79	Cardiology fellows-in-training are exposed to relatively high levels of radiation in the cath lab compared with staff interventional cardiologists' insights from the RECAP trial. Netherlands Heart Journal, 2019, 27, 330-333.	0.8	4
80	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. Journal of Thrombosis and Thrombolysis, 2019, 48, 42-51.	2.1	5
81	IMPACT OF PERCUTANEOUS CORONARY INTERVENTION COMPLEXITY IN REAL-WORLD PRACTICE. Journal of the American College of Cardiology, 2019, 73, 1274.	2.8	0
82	Temporal Trends in Statin Prescriptions and Residual Cholesterol Risk in Patients With Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2019, 123, 1788-1795.	1.6	7
83	Leave nothing behind: Promising results for coronary drug-coated balloons in clinical practice. Catheterization and Cardiovascular Interventions, 2019, 93, 189-190.	1.7	1
84	Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial). American Journal of Cardiology, 2019, 123, 1494-1500.	1.6	19
85	The link between anemia and adverse outcomes in patients with acute coronary syndrome. Expert Review of Cardiovascular Therapy, 2019, 17, 151-159.	1.5	10
86	Value of the SYNTAX Score in ST-Elevation Myocardial Infarction Patients With a Concomitant Chronic Total Coronary Occlusion (from the EXPLORE Trial). American Journal of Cardiology, 2019, 123, 1035-1043.	1.6	6
87	Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clinical Research in Cardiology, 2019, 108, 643-650.	3.3	21
88	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. American Journal of Cardiology, 2019, 123, 709-716.	1.6	9
89	Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. Catheterization and Cardiovascular Interventions, 2019, 94, 53-60.	1.7	2
90	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. Circulation: Cardiovascular Interventions, 2019, 12, e007411.	3.9	55

#	ARTICLE	IF	CITATIONS
91	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. Catheterization and Cardiovascular Interventions, 2019, 93, E112-E119.	1.7	16
92	Temporal trends, determinants, and impact of high-intensity statin prescriptions after percutaneous coronary intervention. American Heart Journal, 2019, 207, 10-18.	2.7	7
93	Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. International Journal of Cardiology, 2019, 275, 31-35.	1.7	12
94	Impact of coronary artery disease and percutaneous coronary intervention in women undergoing transcatheter aortic valve replacement: From the WIN-TAVI registry. Catheterization and Cardiovascular Interventions, 2019, 93, 1124-1131.	1.7	22
95	Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial. Catheterization and Cardiovascular Interventions, 2019, 93, 216-221.	1.7	4
96	Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction. Heart, 2018, 104, 1432-1438.	2.9	55
97	Long-term outcomes of a Caucasian cohort presenting with acute coronary syndrome and/or out-of-hospital cardiac arrest caused by coronary spasm. Netherlands Heart Journal, 2018, 26, 26-33.	0.8	10
98	Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. International Journal of Cardiology, 2018, 263, 24-28.	1.7	6
99	Revascularization Strategies in Cardiogenic Shock Patients With MVD. Journal of the American College of Cardiology, 2018, 71, 857-859.	2.8	5
100	Evaluation of the Impact of a Chronic Total Coronary Occlusion on Ventricular Arrhythmias and Long-Term Mortality in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverter-Defibrillator (the eCTOPY-IN-ICD Study). Journal of the American Heart Association, 2018, 7,	3.7	13
101	Patient delay in women with STEMI: Time to raise awareness. International Journal of Cardiology, 2018, 262, 30-31.	1.7	1
102	Collateral Quality Decay Several Days After Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2018, 11, 511-512.	2.9	0
103	Reply. JACC: Cardiovascular Interventions, 2018, 11, 506-507.	2.9	0
104	Recurrent myocardial infarction in a 47-year-old woman with a mechanical mitral valve prosthesis: Atherosclerosis, embolism, or spasm?. Catheterization and Cardiovascular Interventions, 2018, 91, 267-270.	1.7	0
105	A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis. JACC: Cardiovascular Interventions, 2018, 11, 275-283.	2.9	88
106	TCT-539 Clinical outcomes in high bleeding risk patients undergoing complex PCI with the Xience everolimus eluting stent: a patient-level pooled analysis from four Xience post-approval trials. Journal of the American College of Cardiology, 2018, 72, B217.	2.8	1
107	TCT-835 Validation of PARIS Risk Scores in Patients Treated With Everolimus-Eluting Stents for Left Main Coronary Artery Disease: Analysis From the EXCEL Trial. Journal of the American College of Cardiology, 2018, 72, B333.	2.8	1
108	Go With the Flow When Instantaneous Wave-Free Ratio-Fractional Flow Reserve Discordance Occurs. JACC: Cardiovascular Interventions, 2018, 11, 2435-2436.	2.9	1

#	ARTICLE	IF	CITATIONS
109	TCT-736 Prevalence and Impact of Bleeding Determinants on Risks for out-of-hospital bleeding and coronary thrombosis in patients undergoing percutaneous coronary intervention: Results from a large single-center PCI Registry. <i>Journal of the American College of Cardiology</i> , 2018, 72, B295.	2.8	0
110	The quest for the optimal treatment for in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 300-301.	1.7	1
111	Paravalvular Leak. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2149-2151.	2.8	6
112	Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. <i>European Heart Journal</i> , 2018, 39, 4101-4108.	2.2	89
113	How to manage chronic total occlusions in the setting of acute myocardial infarction complicated by cardiogenic shock?. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 464-465.	1.7	0
114	Determinants of Significant Out-Of-Hospital Bleeding in Patients Undergoing Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1997-2005.	3.4	19
115	Assessing and minimizing the risk of percutaneous coronary intervention in patients with chronic kidney disease. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 825-835.	1.5	16
116	CTCA for detection of significant coronary artery disease in routine TAVI work-up. <i>Netherlands Heart Journal</i> , 2018, 26, 591-599.	0.8	50
117	Impact of Baseline Atrial Fibrillation on Outcomes Among Women Who Underwent Contemporary Transcatheter Aortic Valve Implantation (from the Win-TAVI Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1909-1916.	1.6	18
118	Impact of collateralisation to a concomitant chronic total occlusion in patients with ST-elevation myocardial infarction: a subanalysis of the EXPLORE randomised controlled trial. <i>Open Heart</i> , 2018, 5, e000810.	2.3	11
119	Letter by Kikkert et al Regarding Article, "Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention: The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)" <i>Circulation</i> , 2018, 138, 214-215.	1.6	0
120	The effect of revascularization of a chronic total coronary occlusion on electrocardiographic variables. A sub-study of the EXPLORE trial. <i>Journal of Electrocardiology</i> , 2018, 51, 906-912.	0.9	6
121	Meta-Analysis Comparing Complete or Culprit Only Revascularization in Patients With Multivessel Disease Presenting With Cardiogenic Shock. <i>American Journal of Cardiology</i> , 2018, 122, 1661-1669.	1.6	8
122	Acute myocardial infarction, chronic total occlusion, and cardiogenic shock: the ultimate triple threat. <i>EuroIntervention</i> , 2018, 14, e252-e254.	3.2	3
123	Impact of Chronic Total Occlusion Location on LV Function in ST-Segment Elevation Myocardial Infarction Patients. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2347-2348.	2.8	5
124	Impact of Collateral Circulation on Survival in ST-Segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention With a Concomitant Chronic Total Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 906-914.	2.9	30
125	Mid-term and long-term safety and efficacy of bioresorbable vascular scaffolds versus metallic everolimus-eluting stents in coronary artery disease: A weighted meta-analysis of seven randomised controlled trials including 5577 patients. <i>Netherlands Heart Journal</i> , 2017, 25, 429-438.	0.8	12
126	Culprit Vessel "Only Versus Multivessel Percutaneous Coronary Intervention in Patients With Cardiogenic Shock Complicating ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	44

#	ARTICLE	IF	CITATIONS
127	Efficacy of the RADPAD Protection Drape in Reducing Operatorsâ€™ Radiation Exposure in the Catheterization Laboratory. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	3.9	48
128	TCT-387 Collateral quality decay several days after primary PCI: a novel observation from the EXPLORE trial.. <i>Journal of the American College of Cardiology</i> , 2017, 70, B159.	2.8	2
129	Improved recovery of regional left ventricular function after PCI of chronic total occlusion in STEMI patients: a cardiovascular magnetic resonance study of the randomized controlled EXPLORE trial. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2017, 19, 53.	3.3	41
130	Meta-analyses and randomized trials investigating percutaneous coronary intervention of chronic total occlusions: what is left to explore?. <i>Journal of Thoracic Disease</i> , 2016, 8, E1100-E1102.	1.4	1
131	Percutaneous Intervention for ConcurrentÂChronic Total Occlusions inÂPatients WithÂSTEMI. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1622-1632.	2.8	300
132	A SMILE and a Frown. <i>Journal of the American College of Cardiology</i> , 2016, 67, 273-274.	2.8	8
133	Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 441-451.	2.1	9
134	The impact of the location of a chronic total occlusion in a non-infarct-related artery on long-term mortality in ST-elevation myocardial infarction patients. <i>EuroIntervention</i> , 2016, 12, 423-430.	3.2	8
135	Physiology-guided myocardial revascularisation in complex multivessel coronary artery disease: beyond the 2014 ESC/EACTS guidelines on myocardial revascularisation. <i>Open Heart</i> , 2015, 2, e000308.	2.3	5
136	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2015, 114, 933-944.	3.4	11
137	Analysis of biomarkers for risk of acute kidney injury after primary angioplasty for acute STâ€segment elevation myocardial infarction: Results of the <scp>HORIZONSâ€AMI</scp> trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 335-342.	1.7	22
138	Performance of currently available risk models in a cohort of mechanically supported high-risk percutaneous coronary intervention â€” From the PROTECT II randomized trial. <i>International Journal of Cardiology</i> , 2015, 189, 272-278.	1.7	9
139	Meta-analysis on the impact of percutaneous coronary intervention of chronic total occlusions on left ventricular function and clinical outcome. <i>International Journal of Cardiology</i> , 2015, 187, 90-96.	1.7	126
140	A Dutch perspective on the ESC/EACTS guidelines on myocardial revascularisation. <i>Netherlands Heart Journal</i> , 2015, 23, 290-291.	0.8	2
141	Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderly. <i>Netherlands Heart Journal</i> , 2015, 23, 477-482.	0.8	8
142	The Role of Percutaneous Haemodynamic Support in High-risk Percutaneous Coronary Intervention and Cardiogenic Shock. <i>Interventional Cardiology Review</i> , 2015, 10, 39.	1.6	2
143	Focus on maximal miniaturisation of transradial coronary access materials and techniques by the Slender Club Japan and Europe: an overview and classification. <i>EuroIntervention</i> , 2015, 10, 1178-1186.	3.2	40
144	Rationale and Technique for Percutaneous Coronary Intervention of Chronic Total Occlusions. , 2015, , 2281-2296.		0

#	ARTICLE	IF	CITATIONS
145	Impact of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump on Prognostically Important Clinical Outcomes in Patients Undergoing High-Risk Percutaneous Coronary Intervention (from the PROTECT II Randomized Trial). American Journal of Cardiology, 2014, 113, 222-228.	1.6	116
146	D-dimer levels predict ischemic and hemorrhagic outcomes after acute myocardial infarction: a HORIZONS-AMI biomarker substudy. Journal of Thrombosis and Thrombolysis, 2014, 37, 155-164.	2.1	49
147	Stent Thrombosis. JACC: Cardiovascular Interventions, 2014, 7, 1081-1092.	2.9	159
148	TCT-196 Meta-Analysis on the impact of percutaneous coronary intervention of Chronic Total Occlusions on Long-term Mortality. Journal of the American College of Cardiology, 2014, 64, B58.	2.8	0
149	Contemporary overview and clinical perspectives of chronic total occlusions. Nature Reviews Cardiology, 2014, 11, 458-469.	13.7	33
150	Fractional Flow Reserve-Guided Percutaneous Coronary Intervention: Does Coronary Pressure Never Lie?. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 294.	0.9	7
151	Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 113, 229-235.	1.6	25
152	Does the Association Between a High Body Mass Index and Hospital Mortality Weigh Heavily on the Association Between a Low Body Mass Index and Hospital Mortality?. Critical Care Medicine, 2014, 42, e79.	0.9	0
153	Long-term mortality after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction in patients with insulin-treated versus non-insulin-treated diabetes mellitus. EuroIntervention, 2014, 10, 90-96.	3.2	26
154	Chronic Total Occlusions. , 2014, , 1-18.		0
155	The impact of multivessel disease with and without a coexisting chronic total occlusion on short- and long-term mortality in ST-elevation myocardial infarction patients with and without cardiogenic shock. European Journal of Heart Failure, 2013, 15, 425-432.	7.1	90
156	Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis, 2013, 35, 200-208.	2.1	6
157	Balance of Ischemia and Bleeding in Selecting an Antithrombotic Regimen. Interventional Cardiology Clinics, 2013, 2, 515-525.	0.4	0
158	Vasoactive and Antiarrhythmic Drugs During Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2013, 2, 665-670.	0.4	0
159	Impact of target vessel on long-term survival after percutaneous coronary intervention for chronic total occlusions. Catheterization and Cardiovascular Interventions, 2013, 82, 76-82.	1.7	46
160	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ, The, 2013, 347, f6530-f6530.	6.0	194
161	Adjunctive thrombus aspiration versus conventional percutaneous coronary intervention in ST-elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2013, 81, 922-929.	1.7	16
162	Long-term clinical outcomes after percutaneous coronary intervention for chronic total occlusions in elderly patients (≥75 Years). Catheterization and Cardiovascular Interventions, 2013, 82, 85-92.	1.7	24

#	ARTICLE	IF	CITATIONS
163	Stent thrombosis after primary angioplasty for STEMI in relation to non-adherence to dual antiplatelet therapy over time: results of the HORIZONS-AMI trial. <i>EuroIntervention</i> , 2013, 8, 1033-1039.	3.2	25
164	Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. <i>EuroIntervention</i> , 2013, 9, 220-227.	3.2	39
165	B-type Natriuretic Peptide and Risk of Contrast-Induced Acute Kidney Injury in Acute ST-Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 813-820.	3.9	41
166	Prognostic impact of a chronic total occlusion in a non-infarct-related artery in patients with ST-segment elevation myocardial infarction: 3-year results from the HORIZONS-AMI trial. <i>European Heart Journal</i> , 2012, 33, 768-775.	2.2	206
167	Clinical Outcomes Following Stent Thrombosis Occurring In-Hospital Versus Out-of-Hospital. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1752-1759.	2.8	51
168	TCT-446 Long-Term Clinical Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions in Elderly Patients (≥75 years): Five-Year Outcomes from a 1,791 Patient Multi-National Registry. <i>Journal of the American College of Cardiology</i> , 2012, 60, B128.	2.8	0
169	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1097-1105.	2.9	101
170	Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1231-1238.	2.9	32
171	Plaque Composition by Intravascular Ultrasound and Distal Embolization After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, S111-S118.	5.3	50
172	Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 165-179.	2.1	14
173	Predictive Value of Plasma Glucose Level on Admission for Short and Long Term Mortality in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2012, 109, 53-59.	1.6	53
174	Gender differences in long-term clinical outcomes after percutaneous coronary intervention of chronic total occlusions. <i>Journal of Invasive Cardiology</i> , 2012, 24, 484-8.	0.4	25
175	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2309-2316.	2.8	49
176	Prognostic Impact of Staged Versus "One-Time" Multivessel Percutaneous Intervention in Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 704-711.	2.8	236
177	Long-Term Outcome of Percutaneous Coronary Intervention for Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 952-961.	2.9	260
178	Long-Term Impact of Chronic Kidney Disease in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1011-1019.	2.9	107
179	Impact of Intravascular Ultrasound Imaging on Early and Late Clinical Outcomes Following Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 974-981.	2.9	106
180	Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1209-1215.	2.9	115

#	ARTICLE	IF	CITATIONS
181	Impact of baseline thrombocytopenia on the early and late outcomes after ST-elevation myocardial infarction treated with primary angioplasty: Analysis from the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. American Heart Journal, 2011, 161, 391-396.	2.7	58
182	Impact of In-Hospital Major Bleeding on Late Clinical Outcomes After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 1750-1756.	2.8	127
183	Two-Year Safety and Effectiveness of Sirolimus-Eluting Stents (from a Prospective Registry). American Journal of Cardiology, 2011, 107, 528-534.	1.6	4
184	Angioscopic and Virtual Histology Intravascular Ultrasound Characteristics of Culprit Lesion Morphology Underlying Coronary Artery Thrombosis. American Journal of Cardiology, 2011, 107, 1285-1290.	1.6	27
185	Long-Term Clinical Outcomes of Percutaneous Coronary Intervention for Chronic Total Occlusions in Patients With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2011, 108, 924-931.	1.6	41
186	Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	28
187	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 654-664.	2.9	329
188	Thrombus Aspiration in Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 643-644.	2.9	1
189	Long-term safety and sustained left ventricular recovery: long-term results of percutaneous left ventricular support with Impella LP2.5 in ST-elevation myocardial infarction. EuroIntervention, 2011, 6, 860-865.	3.2	26
190	Healing of a coronary artery dissection detected by intravascular ultrasound and optical coherence tomography. EuroIntervention, 2011, 7, 288-289.	3.2	2
191	Stents farmacolÃ³gicos eluidores de everolimus na prÃ¡tica no mundo real. Revista Brasileira De Cardiologia Invasiva, 2011, 19, 351-352.	0.1	0
192	Evaluating the need for a practical risk score to predict major bleeding in acute coronary syndromes. Interventional Cardiology, 2010, 2, 757-759.	0.0	0
193	Clinical Studies with Sirolimus, Zotarolimus, Everolimus and Biolimus A9 Drug- Eluting Stent Systems. Current Pharmaceutical Design, 2010, 16, 4012-4024.	1.9	10
194	Would SYNTAX have been a positive trial if XIENCE V had been used instead of TAXUS?. Netherlands Heart Journal, 2010, 18, 451-453.	0.8	24
195	Relation of Multivessel Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction to Outcome and/or Non-Infarct Artery Intervention of a Chronic Total Occlusion. American Journal of Cardiology, 2010, 105, 902-903.	1.6	1
196	Effect of Multivessel Coronary Disease With or Without Concurrent Chronic Total Occlusion on One-Year Mortality in Patients Treated With Primary Percutaneous Coronary Intervention for Cardiogenic Shock. American Journal of Cardiology, 2010, 105, 955-959.	1.6	105
197	Rationale and design of EXPLORE: a randomized, prospective, multicenter trial investigating the impact of recanalization of a chronic total occlusion on left ventricular function in patients after primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Trials, 2010, 11, 89.	1.6	58
198	Primary percutaneous coronary intervention for ST elevation myocardial infarction in octogenarians: trends and outcomes. Heart, 2010, 96, 843-847.	2.9	60

#	ARTICLE	IF	CITATIONS
199	Prevalence and impact of a chronic total occlusion in a non-infarct-related artery on long-term mortality in diabetic patients with ST elevation myocardial infarction. <i>Heart</i> , 2010, 96, 1968-1972.	2.9	52
200	The Doppler flow wire in acute myocardial infarction. <i>Heart</i> , 2010, 96, 631-635.	2.9	14
201	Right ventricular dysfunction is an independent predictor for mortality in ST-elevation myocardial infarction patients presenting with cardiogenic shock on admission. <i>European Journal of Heart Failure</i> , 2010, 12, 276-282.	7.1	57
202	Current status of the Xience V [®] everolimus-eluting coronary stent system. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1363-1374.	1.5	11
203	In-Stent Restenosis in the Drug-Eluting Stent Era. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1897-1907.	2.8	663
204	One-year clinical outcome after treatment of bare-metal stent in-stent restenosis with the paclitaxel-eluting stent in an unselected cohort. <i>International Journal of Cardiology</i> , 2010, 145, 608-609.	1.7	0
205	Mitral regurgitation is an independent predictor of 1-year mortality in ST-elevation myocardial infarction patients presenting in cardiogenic shock on admission.. <i>Acute Cardiac Care</i> , 2010, 12, 51-57.	0.2	24
206	Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 339-347.	3.9	109
207	Evaluation of the Effect of a Concurrent Chronic Total Occlusion on Long-Term Mortality and Left Ventricular Function in Patients After Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1128-1134.	2.9	208
208	Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions: The SPIRIT II Trial. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 339-347.	3.9	15
209	Prognostic Value of Free Plasma Homocysteine Levels in Patients Hospitalized With Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2008, 102, 135-139.	1.6	22